The global subcutaneous biologics market is rising due to growing demand for patient-friendly self-administrable therapies and the shift toward biologic drugs with targeted mechanisms of action. The ...

aDepartment of Medicine ‘B’, Sheba Medical Center, Ramat Gan, Israel Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been increasingly ...

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...

AstraZeneca has announced that Saphnelo (anifrolumab) has been recommended for approval in the European Union (EU) as a self-administered once-weekly pre-filled pen for adult patients with systemic ...

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster administration and broader access to immunotherapy. The FDA approved Merck’s ...

The FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for solid tumors in patients 12 years or older. Recommended dosages are 395 mg/4800 U every 3 weeks or 790 mg/9600 U every 6 ...

Introduction: Subcutaneous (SC) administration of the anti-CD38 antibody isatuximab (Isa) by an on-body delivery system (OBDS), plus pomalidomide-dexamethasone, has demonstrated safety and efficacy ...

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...